Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: Joe Wesley who wrote (2539)	4/7/1999 9:20:00 PM
From: Art Bechhoefer	Read Replies (1) \| Respond to of 4676

I spoke with Ian Mortimer, investor relations at INEX PHARMACEUTICALS in Vancouver yesterday. Inex makes delivery systems that are designed to bypass the liver, blood-brain barrier, etc. Inex did some research for ISIS PHARMACEUTICALS in order to evaluate whether the Inex delivery systems would make antisense products more effective, but the research ended when ISIS adopted a policy of testing without confining the compounds to a particular delivery system or particular part of the body. From my own non-professional point of view, it seems that ISIS is concentrating on compounds that can go anywhere in the body and find the malignant cells and make it difficult for them to reproduce. We need more information on progress on all six of the compounds currently being tested.